Nxera Pharma Q2 2026 Results

Nxera Pharma reported its consolidated results for the second quarter ended 30 June 2026, showing a significant improvement in financial performance. Revenue increased to JPY 18,910 million (US$119.6 million), up from JPY 15,095 million in the prior year period, driven by eight R&D milestone events. The company achieved operating profit of JPY 1,881 million versus an operating loss of JPY 2,756 million in the prior year, and net profit of JPY 1,591 million versus a net loss of JPY 3,137 million. Key operational highlights included a licensing agreement with Santhera Pharmaceuticals for vamorolone in Japan, South Korea, Australia, and New Zealand; positive Phase 3 results for daridorexant in insomnia; marketing approval for QUVIVIQ in Taiwan; and progress in partnered programs, including milestone payments from Neurocrine Biosciences, AbbVie, and Eli Lilly. Notably, Eli Lilly completed its acquisition of KC Pharmaceuticals, in which Nxera retains rights to future milestone and royalty payments. Nxera also signed a licensing agreement with a newly established company (NewCo) for a GPCR-targeted program.